Moleculin Biotech, Inc. reports developments as a clinical-stage pharmaceutical company advancing drug candidates for hard-to-treat tumors and viruses. Its lead program is Annamycin, also known as naxtarubicin, a next-generation anthracycline designed to avoid cardiotoxicity and multidrug resistance, with development focused on relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
Recurring news covers Annamycin clinical and preclinical data, the MIRACLE study of Annamycin in combination with cytarabine, oncology conference presentations, intellectual-property protection for liposomal Annamycin, and corporate financial updates. Additional pipeline coverage includes WP1066, an immune/transcription modulator targeting p-STAT3 and other oncogenic transcription factors, and WP1122, an antimetabolite program for pathogenic viruses and cancer indications.
Moleculin Biotech announced significant preclinical findings on Annamycin at the AACR Annual Meeting, which took place from June 22-24, 2020. The poster presentation highlighted Annamycin's ability to achieve high concentrations in lung tissues, leading to superior anti-tumor efficacy against lung-localized tumors in mice. Annamycin demonstrated nearly six times the lung accumulation compared to doxorubicin, indicating potential for improved treatment outcomes in patients with metastatic lung cancer. The company aims to explore Annamycin's clinical applications further.
Moleculin Biotech, Inc. (Nasdaq: MBRX) will present at the virtual Life Sciences Investor Forum on June 25, 2020, from 1:30 PM to 2:00 PM ET. CEO Walter Klemp will lead the presentation, allowing real-time questions from investors. An archived webcast will be available for those who miss the live event. Investors are encouraged to pre-register via the event's page. Moleculin focuses on developing oncology drug candidates targeting resistant tumors, including Annamycin for acute myeloid leukemia, WP1066 for brain tumors, and WP1220 for cutaneous T-cell lymphoma.
Moleculin Biotech, Inc. (Nasdaq: MBRX) announced confirmed in vitro testing results demonstrating the antiviral potential of WP1122 against Human Coronavirus 229E, a surrogate for SARS-CoV-2, on June 1, 2020. The company plans to pursue further in vitro and in vivo studies, anticipating an IND filing for COVID-19 treatment by the end of 2020. Moleculin intends to leverage non-GLP toxicology data in its IND submission. The FDA's guidance was received positively, helping shape the company’s clinical development strategy for WP1122.